Annovis Bio, Inc. ANVS
1.21 USD +0.12 (+11.01%)
At closeNov 4, 2026, 7:59 PM EST
0.93 -0.28 -23.17%
After hours · Nov 4, 7:59 PM ET
1.10 Day range 1.25
0.93 52-week range 5.50
- YTD
- -65.03%
- 1 year
- -35.98%
- Market cap
- 51.64M
- EPS (ttm)
- -1.75
- Shares out
- 13.80M
- Forward P/E
- -2.77
- YTD return
- -65.03%
- 1-year return
- -35.98%
- Volume
- 1.43M
- Avg volume
- 940.80K
- Open
- 1.12
- Previous close
- 1.09
- Day's range
- 1.10 – 1.25
- 52-week range
- 0.93 – 5.50
- Analysts
- Buy
- Price target
- 34.80 (+2776.0%)
- Earnings date
- Aug 14, 2024
5D +0.20 (+19.80%)
Key statistics
- Enterprise value
- 47.66M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.57M
- Total cash
- 12.64M
- Total debt
- 0
- Return on equity
- -596.70%
- Short % of float
- 11.95%
- 50-day average
- 7.29
- 200-day average
- 8.47
Analyst view
Consensus: buy
Buy
Price target (mean) 34.80 +2776.0% upside
Now 1.21
- Target (low)
- 21.00
- Target (mean)
- 34.80
- Target (high)
- 72.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.20.
Financials — quick view
ANVS Revenue — quarterly 0
ANVS Net income — quarterly -14.82M
ANVS EPS — quarterly -0.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.64 | -0.97 | -0.33 | -51.56% |
| Aug 14, 2024 | Jun 1, 2024 | -0.70 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.70 | -0.44 | +0.26 | +37.14% |
| May 13, 2024 | Mar 1, 2024 | -0.87 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.87 | -0.72 | +0.15 | +17.24% |
| Mar 29, 2024 | Dec 1, 2023 | -1.35 | -1.09 | +0.26 | +19.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 25, 2024 | Maxim Group | up | Hold | Buy |
| Aug 15, 2024 | EF Hutton | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | EF Hutton | init | — | Buy |
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- annovisbio.com
News
Annovis Bio Plans To Commence Common Stock Offering; Terms Undisclosed 
Annovis Bio Obtains Noncompliance Notice From NYSE 
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE 
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 
Annovis to Attend the CTAD 2026 with Three Presentations 
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease 
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner 
Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA - Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7
Annovis to Host Corporate Update Webinar on September 2, 2026
Your note
Sign in to keep a note on ANVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUCK CLAUDINE | Director | Stock Award(Grant) | Nov 19, 2023 | 7,567 |
| HAGOPIAN HENRY III | Chief Financial Officer | Stock Award(Grant) | Nov 19, 2023 | 1,824 |
| HOFFMAN MICHAEL B | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Nov 19, 2023 | 0 |
| MACCECCHINI MARIA-LUISA | Chief Executive Officer | Stock Gift | Mar 27, 2024 | 1,068,460 |
| MCCARTHY REID S. | Director | Stock Award(Grant) | Nov 19, 2023 | 8,129 |
| WHITE MARK K. | Director | Stock Award(Grant) | Nov 19, 2023 | 61,177 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.76% | 380,255 | 1.91M | Sep 29, 2024 |
| Blackrock Inc. | 0.74% | 101,495 | 508.49K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.74% | 102,692 | 514.49K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.72% | 99,114 | 496.56K | Sep 29, 2024 |
| Group One Trading, L.P. | 0.38% | 52,767 | 264.36K | Sep 29, 2024 |
| Quest Partners LLC | 0.33% | 46,002 | 230.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.91% | 263,507 | 1.32M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 110,600 | 554.11K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 55,356 | 277.33K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.15% | 21,000 | 105.21K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.14% | 18,945 | 94.91K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 17,944 | 89.90K | Oct 30, 2024 |